ID   FGFR1_HUMAN             Reviewed;         822 AA.
AC   P11362; A8K6T9; A8K8V5; C1KBH8; P17049; Q02063; Q02065; Q14306;
AC   Q14307; Q53H63; Q5BJG2; Q8N685; Q9UD50; Q9UDF0; Q9UDF1; Q9UDF2;
DT   01-JUL-1989, integrated into UniProtKB/Swiss-Prot.
DT   01-MAY-1991, sequence version 3.
DT   02-NOV-2010, entry version 156.
DE   RecName: Full=Basic fibroblast growth factor receptor 1;
DE            Short=FGFR-1;
DE            Short=bFGF-R-1;
DE            EC=2.7.10.1;
DE   AltName: Full=Fms-like tyrosine kinase 2;
DE            Short=FLT-2;
DE   AltName: Full=Proto-oncogene c-Fgr;
DE   AltName: CD_antigen=CD331;
DE   Flags: Precursor;
GN   Name=FGFR1; Synonyms=FGFBR, FLG, FLT2;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Euarchontoglires; Primates; Haplorrhini;
OC   Catarrhini; Hominidae; Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 15).
RC   TISSUE=Placenta;
RX   MEDLINE=90290512; PubMed=2162671; DOI=10.1016/0006-291X(90)90384-Y;
RA   Itoh N., Terachi T., Ohta M., Seo M.K.;
RT   "The complete amino acid sequence of the shorter form of human basic
RT   fibroblast growth factor receptor deduced from its cDNA.";
RL   Biochem. Biophys. Res. Commun. 169:680-685(1990).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1).
RC   TISSUE=Neonatal brain stem;
RX   MEDLINE=90360977; PubMed=1697263;
RA   Dionne C.A., Crumley G.R., Bellot F., Kaplow J.M., Searfoss G.,
RA   Ruta M., Burgess W.H., Jaye M., Schlessinger J.;
RT   "Cloning and expression of two distinct high-affinity receptors cross-
RT   reacting with acidic and basic fibroblast growth factors.";
RL   EMBO J. 9:2685-2692(1990).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORMS 6; 15; 17 AND 18).
RX   MEDLINE=90355989; PubMed=2167437;
RA   Johnson D.E., Lee P.L., Lu J., Williams L.T.;
RT   "Diverse forms of a receptor for acidic and basic fibroblast growth
RT   factors.";
RL   Mol. Cell. Biol. 10:4728-4736(1990).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1).
RC   TISSUE=Placenta;
RX   MEDLINE=90245600; PubMed=2159626; DOI=10.1093/nar/18.7.1906;
RA   Isacchi A., Bergonzoni L., Sarmientos P.;
RT   "Complete sequence of a human receptor for acidic and basic fibroblast
RT   growth factors.";
RL   Nucleic Acids Res. 18:1906-1906(1990).
RN   [5]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 14).
RC   TISSUE=Teratocarcinoma;
RX   MEDLINE=92118394; PubMed=1722683;
RA   Wennstroem S., Sandstroem C., Claesson-Welsh L.;
RT   "cDNA cloning and expression of a human FGF receptor which binds
RT   acidic and basic FGF.";
RL   Growth Factors 4:197-208(1991).
RN   [6]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 14).
RX   MEDLINE=92118399; PubMed=1662973;
RA   Kiefer M.C., Baird A., George-Nascimento C., Nguyen T., Mason O.B.,
RA   Boley L.J., Valenzuela P., Barr P.J.;
RT   "Molecular cloning of a human basic fibroblast growth factor receptor
RT   cDNA and expression of a biologically active extracellular domain in a
RT   baculovirus system.";
RL   Growth Factors 5:115-127(1991).
RN   [7]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORMS 1; 6; 14; 15 AND 16).
RC   TISSUE=Lung;
RX   MEDLINE=91319400; PubMed=1650441;
RA   Eisemann A., Ahn J.A., Graziani G., Tronick S.R., Ron D.;
RT   "Alternative splicing generates at least five different isoforms of
RT   the human basic-FGF receptor.";
RL   Oncogene 6:1195-1202(1991).
RN   [8]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORMS 1; 2; 3; 4; 5; 6; 7; 8; 9; 10;
RP   11; 12 AND 13).
RC   TISSUE=Liver;
RX   MEDLINE=91126480; PubMed=1846977; DOI=10.1126/science.1846977;
RA   Hou J., Kan M., McKeehan K., McBride G., Adams P., McKeehan W.L.;
RT   "Fibroblast growth factor receptors from liver vary in three
RT   structural domains.";
RL   Science 251:665-668(1991).
RN   [9]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1).
RX   MEDLINE=92282615; PubMed=1317750;
RA   Hattori Y., Odagiri H., Katoh O., Sakamoto H., Morita T.,
RA   Shimotohno K., Tobinai K., Sugimura T., Terada M.;
RT   "K-sam-related gene, N-sam, encodes fibroblast growth factor receptor
RT   and is expressed in T-lymphocytic tumors.";
RL   Cancer Res. 52:3367-3371(1992).
RN   [10]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 19).
RA   Miura S., Miura K., Yoshiura K.-I.;
RT   "A missense mutation in alternatively spliced exon 8A encoding
RT   immunoglobulin-like domain IIIb of FGFR1 in a female patient with
RT   Kallmann syndrome.";
RL   Submitted (MAR-2009) to the EMBL/GenBank/DDBJ databases.
RN   [11]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORMS 6 AND 14).
RC   TISSUE=Placenta, and Testis;
RX   PubMed=14702039; DOI=10.1038/ng1285;
RA   Ota T., Suzuki Y., Nishikawa T., Otsuki T., Sugiyama T., Irie R.,
RA   Wakamatsu A., Hayashi K., Sato H., Nagai K., Kimura K., Makita H.,
RA   Sekine M., Obayashi M., Nishi T., Shibahara T., Tanaka T., Ishii S.,
RA   Yamamoto J., Saito K., Kawai Y., Isono Y., Nakamura Y., Nagahari K.,
RA   Murakami K., Yasuda T., Iwayanagi T., Wagatsuma M., Shiratori A.,
RA   Sudo H., Hosoiri T., Kaku Y., Kodaira H., Kondo H., Sugawara M.,
RA   Takahashi M., Kanda K., Yokoi T., Furuya T., Kikkawa E., Omura Y.,
RA   Abe K., Kamihara K., Katsuta N., Sato K., Tanikawa M., Yamazaki M.,
RA   Ninomiya K., Ishibashi T., Yamashita H., Murakawa K., Fujimori K.,
RA   Tanai H., Kimata M., Watanabe M., Hiraoka S., Chiba Y., Ishida S.,
RA   Ono Y., Takiguchi S., Watanabe S., Yosida M., Hotuta T., Kusano J.,
RA   Kanehori K., Takahashi-Fujii A., Hara H., Tanase T.-O., Nomura Y.,
RA   Togiya S., Komai F., Hara R., Takeuchi K., Arita M., Imose N.,
RA   Musashino K., Yuuki H., Oshima A., Sasaki N., Aotsuka S.,
RA   Yoshikawa Y., Matsunawa H., Ichihara T., Shiohata N., Sano S.,
RA   Moriya S., Momiyama H., Satoh N., Takami S., Terashima Y., Suzuki O.,
RA   Nakagawa S., Senoh A., Mizoguchi H., Goto Y., Shimizu F., Wakebe H.,
RA   Hishigaki H., Watanabe T., Sugiyama A., Takemoto M., Kawakami B.,
RA   Yamazaki M., Watanabe K., Kumagai A., Itakura S., Fukuzumi Y.,
RA   Fujimori Y., Komiyama M., Tashiro H., Tanigami A., Fujiwara T.,
RA   Ono T., Yamada K., Fujii Y., Ozaki K., Hirao M., Ohmori Y.,
RA   Kawabata A., Hikiji T., Kobatake N., Inagaki H., Ikema Y., Okamoto S.,
RA   Okitani R., Kawakami T., Noguchi S., Itoh T., Shigeta K., Senba T.,
RA   Matsumura K., Nakajima Y., Mizuno T., Morinaga M., Sasaki M.,
RA   Togashi T., Oyama M., Hata H., Watanabe M., Komatsu T.,
RA   Mizushima-Sugano J., Satoh T., Shirai Y., Takahashi Y., Nakagawa K.,
RA   Okumura K., Nagase T., Nomura N., Kikuchi H., Masuho Y., Yamashita R.,
RA   Nakai K., Yada T., Nakamura Y., Ohara O., Isogai T., Sugano S.;
RT   "Complete sequencing and characterization of 21,243 full-length human
RT   cDNAs.";
RL   Nat. Genet. 36:40-45(2004).
RN   [12]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 14).
RC   TISSUE=Colon;
RA   Suzuki Y., Sugano S., Totoki Y., Toyoda A., Takeda T., Sakaki Y.,
RA   Tanaka A., Yokoyama S.;
RL   Submitted (APR-2005) to the EMBL/GenBank/DDBJ databases.
RN   [13]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA], AND VARIANTS SER-22; ARG-818 AND
RP   CYS-822.
RG   NIEHS SNPs program;
RL   Submitted (MAR-2004) to the EMBL/GenBank/DDBJ databases.
RN   [14]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORMS 4; 14 AND 15), AND
RP   VARIANT GLY-213.
RC   TISSUE=Pancreas, Testis, and Uterus;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA
RT   project: the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [15]
RP   NUCLEOTIDE SEQUENCE [MRNA] OF 1-370 (ISOFORM 15), AND PROTEIN SEQUENCE
RP   OF 22-129 (ISOFORM 15).
RX   MEDLINE=94347757; PubMed=7520751; DOI=10.1021/bi00200a003;
RA   Pantoliano M.W., Horlick R.A., Springer B.A., Van Dyk D.E., Tobery T.,
RA   Wetmore D.R., Lear J.D., Nahapetian A.T., Bradley J.D., Sisk W.P.;
RT   "Multivalent ligand-receptor binding interactions in the fibroblast
RT   growth factor system produce a cooperative growth factor and heparin
RT   mechanism for receptor dimerization.";
RL   Biochemistry 33:10229-10248(1994).
RN   [16]
RP   PROTEIN SEQUENCE OF 81-100 (ISOFORMS 1/2/4/5/14/16).
RX   MEDLINE=94354840; PubMed=8074689; DOI=10.1006/bbrc.1994.2203;
RA   Rusnati M., Coltrini D., Caccia P., Dell'Era P., Zoppetti G.,
RA   Oreste P., Valsasina B., Presta M.;
RT   "Distinct role of 2-O-, N-, and 6-O-sulfate groups of heparin in the
RT   formation of the ternary complex with basic fibroblast growth factor
RT   and soluble FGF receptor-1.";
RL   Biochem. Biophys. Res. Commun. 203:450-458(1994).
RN   [17]
RP   NUCLEOTIDE SEQUENCE [MRNA] OF 201-822 (ISOFORMS 1/6/10/14/15).
RA   Ruta M., Howk R., Ricca G., Drohan W., Zabelshansky M., Laureys G.,
RA   Barton D.E., Francke U., Schlessinger J., Givol D.;
RT   "A novel protein tyrosine kinase gene whose expression is modulated
RT   during endothelial cell differentiation.";
RL   Oncogene 3:9-15(1988).
RN   [18]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 313-391 (ISOFORMS 17/18),
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 313-360 (ISOFORMS
RP   1/2/4/5/6/7/8/9/10/11/12/13/14/15), NUCLEOTIDE SEQUENCE [GENOMIC DNA /
RP   MRNA] OF 313-360 (ISOFORM 19), AND TISSUE SPECIFICITY.
RC   TISSUE=Foreskin fibroblast, and Umbilical vein;
RX   MEDLINE=91342665; PubMed=1652059;
RA   Johnson D.E., Lu J., Chen H., Werner S., Williams L.T.;
RT   "The human fibroblast growth factor receptor genes: a common
RT   structural arrangement underlies the mechanisms for generating
RT   receptor forms that differ in their third immunoglobulin domain.";
RL   Mol. Cell. Biol. 11:4627-4634(1991).
RN   [19]
RP   PARTIAL NUCLEOTIDE SEQUENCE [MRNA].
RX   MEDLINE=91141499; PubMed=1847500;
RA   Gutkind S.J., Link D.C., Katamine S., Lacal P., Miki T., Ley T.J.,
RA   Robbins K.C.;
RT   "A novel c-fgr exon utilized in Epstein-Barr virus-infected B
RT   lymphocytes but not in normal monocytes.";
RL   Mol. Cell. Biol. 11:1500-1507(1991).
RN   [20]
RP   MUTAGENESIS OF TYR-766.
RX   MEDLINE=92357144; PubMed=1379697; DOI=10.1038/358678a0;
RA   Peters K.G., Marie J., Wilson E., Ives H.E., Escobedo J.,
RA   del Rosario M., Mirda D., Williams L.T.;
RT   "Point mutation of an FGF receptor abolishes phosphatidylinositol
RT   turnover and Ca2+ flux but not mitogenesis.";
RL   Nature 358:678-681(1992).
RN   [21]
RP   MUTAGENESIS OF TYR-766.
RX   MEDLINE=92357145; PubMed=1379698; DOI=10.1038/358681a0;
RA   Mohammadi M., Dionne C.A., Li W., Lin N., Spivak T., Honegger A.M.,
RA   Jaye M., Schlessinger J.;
RT   "Point mutation in FGF receptor eliminates phosphatidylinositol
RT   hydrolysis without affecting mitogenesis.";
RL   Nature 358:681-684(1992).
RN   [22]
RP   INTERACTION WITH FGF1, AND PHOSPHORYLATION.
RX   MEDLINE=98318105; PubMed=9655399; DOI=10.1038/31741;
RA   DiGabriele A.D., Lax I., Chen D.I., Svahn C.M., Jaye M.,
RA   Schlessinger J., Hendrickson W.A.;
RT   "Structure of a heparin-linked biologically active dimer of fibroblast
RT   growth factor.";
RL   Nature 393:812-817(1998).
RN   [23]
RP   CHROMOSOMAL TRANSLOCATION WITH FGFR1OP.
RX   MEDLINE=99135870; PubMed=9949182;
RA   Popovici C., Zhang B., Gregoire M.-J., Jonveaux P.,
RA   Lafage-Pochitaloff M., Birnbaum D., Pebusque M.-J.;
RT   "The t(6;8)(q27;p11) translocation in a stem cell myeloproliferative
RT   disorder fuses a novel gene, FOP, to fibroblast growth factor receptor
RT   1.";
RL   Blood 93:1381-1389(1999).
RN   [24]
RP   INTERACTION WITH GRB10.
RX   PubMed=10454568;
RA   Wang J., Dai H., Yousaf N., Moussaif M., Deng Y., Boufelliga A.,
RA   Swamy O.R., Leone M.E., Riedel H.;
RT   "Grb10, a positive, stimulatory signaling adapter in platelet-derived
RT   growth factor BB-, insulin-like growth factor I-, and insulin-mediated
RT   mitogenesis.";
RL   Mol. Cell. Biol. 19:6217-6228(1999).
RN   [25]
RP   CHROMOSOMAL TRANSLOCATION WITH CEP110.
RX   PubMed=10688839;
RA   Guasch G., Mack G.J., Popovici C., Dastugue N., Birnbaum D.,
RA   Rattner J.B., Pebusque M.-J.;
RT   "FGFR1 is fused to the centrosome-associated protein CEP110 in the
RT   8p12 stem cell myeloproliferative disorder with t(8;9)(p12;q33).";
RL   Blood 95:1788-1796(2000).
RN   [26]
RP   INTERACTION WITH SHB, AND MUTAGENESIS OF TYR-766.
RX   PubMed=12181353; DOI=10.1091/mbc.E02-02-0103;
RA   Cross M.J., Lu L., Magnusson P., Nyqvist D., Holmqvist K., Welsh M.,
RA   Claesson-Welsh L.;
RT   "The Shb adaptor protein binds to tyrosine 766 in the FGFR-1 and
RT   regulates the Ras/MEK/MAPK pathway via FRS2 phosphorylation in
RT   endothelial cells.";
RL   Mol. Biol. Cell 13:2881-2893(2002).
RN   [27]
RP   CHROMOSOMAL TRANSLOCATION WITH FGFR1OP2.
RX   PubMed=15034873; DOI=10.1002/gcc.20023;
RA   Grand E.K., Grand F.H., Chase A.J., Ross F.M., Corcoran M.M.,
RA   Oscier D.G., Cross N.C.P.;
RT   "Identification of a novel gene, FGFR1OP2, fused to FGFR1 in 8p11
RT   myeloproliferative syndrome.";
RL   Genes Chromosomes Cancer 40:78-83(2004).
RN   [28]
RP   GLYCOSYLATION [LARGE SCALE ANALYSIS] AT ASN-296, AND MASS
RP   SPECTROMETRY.
RC   TISSUE=Plasma;
RX   PubMed=16335952; DOI=10.1021/pr0502065;
RA   Liu T., Qian W.-J., Gritsenko M.A., Camp D.G. II, Monroe M.E.,
RA   Moore R.J., Smith R.D.;
RT   "Human plasma N-glycoproteome analysis by immunoaffinity subtraction,
RT   hydrazide chemistry, and mass spectrometry.";
RL   J. Proteome Res. 4:2070-2080(2005).
RN   [29]
RP   CHROMOSOMAL TRANSLOCATION WITH FGFR1OP2.
RX   PubMed=16946300; DOI=10.1182/blood-2006-06-026666;
RA   Gu T.-L., Goss V.L., Reeves C., Popova L., Nardone J., Macneill J.,
RA   Walters D.K., Wang Y., Rush J., Comb M.J., Druker B.J.,
RA   Polakiewicz R.D.;
RT   "Phosphotyrosine profiling identifies the KG-1 cell line as a model
RT   for the study of FGFR1 fusions in acute myeloid leukemia.";
RL   Blood 108:4202-4204(2006).
RN   [30]
RP   CHROMOSOMAL TRANSLOCATION WITH FGFR1OP2.
RX   PubMed=17389761; DOI=10.1182/blood-2006-12-065615;
RA   Dong S., Kang S., Gu T., Kardar S., Fu H., Lonial S., Khoury H.J.,
RA   Khuri F., Chen J.;
RT   "14-3-3 integrates pro-survival signals mediated by the AKT and MAPK
RT   pathways in ZNF198-FGFR1 transformed hematopoietic cells.";
RL   Blood 110:360-369(2007).
RN   [31]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT TYR-653, AND MASS
RP   SPECTROMETRY.
RC   TISSUE=Lung carcinoma;
RX   PubMed=18083107; DOI=10.1016/j.cell.2007.11.025;
RA   Rikova K., Guo A., Zeng Q., Possemato A., Yu J., Haack H., Nardone J.,
RA   Lee K., Reeves C., Li Y., Hu Y., Tan Z., Stokes M., Sullivan L.,
RA   Mitchell J., Wetzel R., Macneill J., Ren J.M., Yuan J.,
RA   Bakalarski C.E., Villen J., Kornhauser J.M., Smith B., Li D., Zhou X.,
RA   Gygi S.P., Gu T.-L., Polakiewicz R.D., Rush J., Comb M.J.;
RT   "Global survey of phosphotyrosine signaling identifies oncogenic
RT   kinases in lung cancer.";
RL   Cell 131:1190-1203(2007).
RN   [32]
RP   X-RAY CRYSTALLOGRAPHY (2.0 ANGSTROMS) OF 464-762.
RX   MEDLINE=96361355; PubMed=8752212; DOI=10.1016/S0092-8674(00)80131-2;
RA   Mohammadi M., Schlessinger J., Hubbard S.R.;
RT   "Structure of the FGF receptor tyrosine kinase domain reveals a novel
RT   autoinhibitory mechanism.";
RL   Cell 86:577-587(1996).
RN   [33]
RP   X-RAY CRYSTALLOGRAPHY (2.4 ANGSTROMS) OF 464-762.
RX   MEDLINE=97284786; PubMed=9139660; DOI=10.1126/science.276.5314.955;
RA   Mohammadi M., McMahon G., Sun L., Tang C., Hirth P., Yeh B.K.,
RA   Hubbard S.R., Schlessinger J.;
RT   "Structures of the tyrosine kinase domain of fibroblast growth factor
RT   receptor in complex with inhibitors.";
RL   Science 276:955-960(1997).
RN   [34]
RP   X-RAY CRYSTALLOGRAPHY (2.8 ANGSTROMS) OF 141-364 IN COMPLEX WITH FGF1.
RX   MEDLINE=20288980; PubMed=10830168; DOI=10.1016/S0092-8674(00)80851-X;
RA   Plotnikov A.N., Hubbard S.R., Schlessinger J., Mohammadi M.;
RT   "Crystal structures of two FGF-FGFR complexes reveal the determinants
RT   of ligand-receptor specificity.";
RL   Cell 101:413-424(2000).
RN   [35]
RP   X-RAY CRYSTALLOGRAPHY (3.0 ANGSTROMS) OF 143-364 IN COMPLEX WITH FGF2
RP   AND HEPARIN.
RX   MEDLINE=20483271; PubMed=11030354; DOI=10.1016/S1097-2765(00)00073-3;
RA   Schlessinger J., Plotnikov A.N., Ibrahimi O.A., Eliseenkova A.V.,
RA   Yeh B.K., Yayon A., Linhardt R.J., Mohammadi M.;
RT   "Crystal structure of a ternary FGF-FGFR-heparin complex reveals a
RT   dual role for heparin in FGFR binding and dimerization.";
RL   Mol. Cell 6:743-750(2000).
RN   [36]
RP   STRUCTURE BY NMR OF 38-124.
RG   RIKEN structural genomics initiative (RSGI);
RT   "Solution structure of the first Ig-like domain of human fibroblast
RT   growth factor receptor 1.";
RL   Submitted (NOV-2005) to the PDB data bank.
RN   [37]
RP   VARIANT PS ARG-252.
RX   MEDLINE=95179173; PubMed=7874169; DOI=10.1038/ng1194-269;
RA   Muenke M., Schell U., Hehr A., Robin N.H., Losken H.W., Schinzel A.,
RA   Pulleyn L.J., Rutland P., Reardon W., Malcolm S., Winter R.M.;
RT   "A common mutation in the fibroblast growth factor receptor 1 gene in
RT   Pfeiffer syndrome.";
RL   Nat. Genet. 8:269-274(1994).
RN   [38]
RP   VARIANT NON-SYNDROMIC TRIGONOCEPHALY THR-300.
RX   PubMed=11173846;
RA   Kress W., Petersen B., Collmann H., Grimm T.;
RT   "An unusual FGFR1 mutation (fibroblast growth factor receptor 1
RT   mutation) in a girl with non-syndromic trigonocephaly.";
RL   Cytogenet. Cell Genet. 91:138-140(2000).
RN   [39]
RP   VARIANTS KAL2 ASP-97; CYS-99; SER-167; TYR-277; MET-607; ARG-666;
RP   ARG-719 AND SER-772.
RX   MEDLINE=22552711; PubMed=12627230; DOI=10.1038/ng1122;
RA   Dode C., Levilliers J., Dupont J.-M., De Paepe A., Le Du N.,
RA   Soussi-Yanicostas N., Coimbra R.S., Delmaghani S.,
RA   Compain-Nouaille S., Baverel F., Pecheux C., Le Tessier D., Cruaud C.,
RA   Delpech M., Speleman F., Vermeulen S., Amalfitano A., Bachelot Y.,
RA   Bouchard P., Cabrol S., Carel J.-C., Delemarre-van de Waal H.,
RA   Goulet-Salmon B., Kottler M.-L., Richard O., Sanchez-Franco F.,
RA   Saura R., Young J., Petit C., Hardelin J.-P.;
RT   "Loss-of-function mutations in FGFR1 cause autosomal dominant Kallmann
RT   syndrome.";
RL   Nat. Genet. 33:463-465(2003).
RN   [40]
RP   VARIANT KAL2 SER-745.
RX   PubMed=15001591; DOI=10.1210/jc.2003-030476;
RA   Sato N., Katsumata N., Kagami M., Hasegawa T., Hori N., Kawakita S.,
RA   Minowada S., Shimotsuka A., Shishiba Y., Yokozawa M., Yasuda T.,
RA   Nagasaki K., Hasegawa D., Hasegawa Y., Tachibana K., Naiki Y.,
RA   Horikawa R., Tanaka T., Ogata T.;
RT   "Clinical assessment and mutation analysis of Kallmann syndrome 1
RT   (KAL1) and fibroblast growth factor receptor 1 (FGFR1, or KAL2) in
RT   five families and 18 sporadic patients.";
RL   J. Clin. Endocrinol. Metab. 89:1079-1088(2004).
RN   [41]
RP   VARIANTS OGD ILE-330; CYS-374 AND ARG-381, AND CHARACTERIZATION OF
RP   VARIANT OGD CYS-374.
RX   PubMed=15625620; DOI=10.1086/427956;
RA   White K.E., Cabral J.M., Davis S.I., Fishburn T., Evans W.E.,
RA   Ichikawa S., Fields J., Yu X., Shaw N.J., McLellan N.J., McKeown C.,
RA   FitzPatrick D., Yu K., Ornitz D.M., Econs M.J.;
RT   "Mutations that cause osteoglophonic dysplasia define novel roles for
RT   FGFR1 in bone elongation.";
RL   Am. J. Hum. Genet. 76:361-367(2005).
RN   [42]
RP   VARIANTS KAL2 ILE-102; ALA-129; MET-273 AND THR-520.
RX   PubMed=15605412; DOI=10.1002/humu.9298;
RA   Albuisson J., Pecheux C., Carel J.-C., Lacombe D., Leheup B.,
RA   Lapuzina P., Bouchard P., Legius E., Matthijs G., Wasniewska M.,
RA   Delpech M., Young J., Hardelin J.-P., Dode C.;
RT   "Kallmann syndrome: 14 novel mutations in KAL1 and FGFR1 (KAL2).";
RL   Hum. Mutat. 25:98-99(2005).
RN   [43]
RP   VARIANTS KAL2 ARG-687 AND SER-745.
RX   PubMed=15845591; DOI=10.1093/humrep/dei052;
RA   Sato N., Hasegawa T., Hori N., Fukami M., Yoshimura Y., Ogata T.;
RT   "Gonadotrophin therapy in Kallmann syndrome caused by heterozygous
RT   mutations of the gene for fibroblast growth factor receptor 1: report
RT   of three families: case report.";
RL   Hum. Reprod. 20:2173-2178(2005).
RN   [44]
RP   VARIANTS OGD ILE-330 AND ARG-381.
RX   PubMed=16470795; DOI=10.1002/ajmg.a.31106;
RA   Farrow E.G., Davis S.I., Mooney S.D., Beighton P., Mascarenhas L.,
RA   Gutierrez Y.R., Pitukcheewanont P., White K.E.;
RT   "Extended mutational analyses of FGFR1 in osteoglophonic dysplasia.";
RL   Am. J. Med. Genet. A 140:537-539(2006).
RN   [45]
RP   VARIANT IHH SER-48, VARIANT IHH/KAL2 LEU-366, AND VARIANTS KAL2
RP   PRO-245; TRP-250; VAL-343; SER-722 AND ILE-795.
RX   PubMed=16882753; DOI=10.1210/jc.2005-2793;
RA   Trarbach E.B., Costa E.M.F., Versiani B., de Castro M.,
RA   Baptista M.T.M., Garmes H.M., de Mendonca B.B., Latronico A.C.;
RT   "Novel fibroblast growth factor receptor 1 mutations in patients with
RT   congenital hypogonadotropic hypogonadism with and without anosmia.";
RL   J. Clin. Endocrinol. Metab. 91:4006-4012(2006).
RN   [46]
RP   VARIANTS KAL2 CYS-78; ILE-102; HIS-224; ASP-237; GLN-254; MET-273;
RP   GLY-274 CYS-339; CYS-346; VAL-538; ARG-703 AND SER-703, AND VARIANT
RP   VAL-769.
RX   PubMed=16764984; DOI=10.1016/j.mce.2006.04.021;
RA   Pitteloud N., Meysing A., Quinton R., Acierno J.S. Jr., Dwyer A.A.,
RA   Plummer L., Fliers E., Boepple P., Hayes F., Seminara S., Hughes V.A.,
RA   Ma J., Bouloux P., Mohammadi M., Crowley W.F. Jr.;
RT   "Mutations in fibroblast growth factor receptor 1 cause Kallmann
RT   syndrome with a wide spectrum of reproductive phenotypes.";
RL   Mol. Cell. Endocrinol. 254:60-69(2006).
RN   [47]
RP   VARIANTS KAL2 SER-178; GLY-622 AND GLN-622.
RX   PubMed=16757108; DOI=10.1016/j.mce.2006.04.006;
RA   Zenaty D., Bretones P., Lambe C., Guemas I., David M., Leger J.,
RA   de Roux N.;
RT   "Paediatric phenotype of Kallmann syndrome due to mutations of
RT   fibroblast growth factor receptor 1 (FGFR1).";
RL   Mol. Cell. Endocrinol. 254:78-83(2006).
RN   [48]
RP   VARIANT IHH/KAL2 SER-237, VARIANTS IHH HIS-722 AND LYS-724,
RP   CHARACTERIZATION OF VARIANT IHH/KAL2 SER-237, AND CHARACTERIZATION OF
RP   VARIANTS IHH HIS-722 AND LYS-724.
RX   PubMed=16606836; DOI=10.1073/pnas.0600962103;
RA   Pitteloud N., Acierno J.S. Jr., Meysing A., Eliseenkova A.V., Ma J.,
RA   Ibrahimi O.A., Metzger D.L., Hayes F.J., Dwyer A.A., Hughes V.A.,
RA   Yialamas M., Hall J.E., Grant E., Mohammadi M., Crowley W.F. Jr.;
RT   "Mutations in fibroblast growth factor receptor 1 cause both Kallmann
RT   syndrome and normosmic idiopathic hypogonadotropic hypogonadism.";
RL   Proc. Natl. Acad. Sci. U.S.A. 103:6281-6286(2006).
RN   [49]
RP   VARIANTS KAL2 PHE-101; TRP-250; ASP-270; ARG-283; CYS-332; ARG-621;
RP   PHE-685; PHE-693 AND SER-772, AND VARIANTS LYS-77 AND CYS-822.
RX   PubMed=17154279; DOI=10.1002/humu.9470;
RA   Dode C., Fouveaut C., Mortier G., Janssens S., Bertherat J.,
RA   Mahoudeau J., Kottler M.-L., Chabrolle C., Gancel A., Francois I.,
RA   Devriendt K., Wolczynski S., Pugeat M., Pineiro-Garcia A., Murat A.,
RA   Bouchard P., Young J., Delpech M., Hardelin J.-P.;
RT   "Novel FGFR1 sequence variants in Kallmann syndrome, and genetic
RT   evidence that the FGFR1c isoform is required in olfactory bulb and
RT   palate morphogenesis.";
RL   Hum. Mutat. 28:97-98(2007).
RN   [50]
RP   VARIANTS [LARGE SCALE ANALYSIS] LEU-125; THR-252 AND LEU-664.
RX   PubMed=17344846; DOI=10.1038/nature05610;
RA   Greenman C., Stephens P., Smith R., Dalgliesh G.L., Hunter C.,
RA   Bignell G., Davies H., Teague J., Butler A., Stevens C., Edkins S.,
RA   O'Meara S., Vastrik I., Schmidt E.E., Avis T., Barthorpe S.,
RA   Bhamra G., Buck G., Choudhury B., Clements J., Cole J., Dicks E.,
RA   Forbes S., Gray K., Halliday K., Harrison R., Hills K., Hinton J.,
RA   Jenkinson A., Jones D., Menzies A., Mironenko T., Perry J., Raine K.,
RA   Richardson D., Shepherd R., Small A., Tofts C., Varian J., Webb T.,
RA   West S., Widaa S., Yates A., Cahill D.P., Louis D.N., Goldstraw P.,
RA   Nicholson A.G., Brasseur F., Looijenga L., Weber B.L., Chiew Y.-E.,
RA   DeFazio A., Greaves M.F., Green A.R., Campbell P., Birney E.,
RA   Easton D.F., Chenevix-Trench G., Tan M.-H., Khoo S.K., Teh B.T.,
RA   Yuen S.T., Leung S.Y., Wooster R., Futreal P.A., Stratton M.R.;
RT   "Patterns of somatic mutation in human cancer genomes.";
RL   Nature 446:153-158(2007).
CC   -!- FUNCTION: Receptor for basic fibroblast growth factor. Receptor
CC       for FGF23 in the presence of KL (By similarity). A shorter form of
CC       the receptor could be a receptor for FGF1 (aFGF).
CC   -!- CATALYTIC ACTIVITY: ATP + a [protein]-L-tyrosine = ADP + a
CC       [protein]-L-tyrosine phosphate.
CC   -!- SUBUNIT: Interacts with SHB. Interacts with KLB (By similarity).
CC       Interacts with KL and FGF23 (By similarity). Interacts with GRB10.
CC   -!- INTERACTION:
CC       P12830:CDH1; NbExp=1; IntAct=EBI-1028277, EBI-727477;
CC       P35222:CTNNB1; NbExp=1; IntAct=EBI-1028277, EBI-491549;
CC       P10686:Plcg1 (xeno); NbExp=3; IntAct=EBI-1028277, EBI-520788;
CC   -!- SUBCELLULAR LOCATION: Membrane; Single-pass type I membrane
CC       protein.
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Alternative splicing; Named isoforms=19;
CC       Name=1; Synonyms=Alpha A1, IV;
CC         IsoId=P11362-1; Sequence=Displayed;
CC       Name=2; Synonyms=Alpha A2;
CC         IsoId=P11362-8; Sequence=VSP_009842, VSP_009843;
CC       Name=3; Synonyms=Alpha A3;
CC         IsoId=P11362-17; Sequence=VSP_009836, VSP_009837;
CC       Name=4; Synonyms=Alpha B1;
CC         IsoId=P11362-2; Sequence=VSP_002960;
CC       Name=5; Synonyms=Alpha B2;
CC         IsoId=P11362-9; Sequence=VSP_002960, VSP_009842, VSP_009843;
CC       Name=6; Synonyms=Beta A1, II, H2;
CC         IsoId=P11362-3; Sequence=VSP_002958;
CC       Name=7; Synonyms=Beta A2;
CC         IsoId=P11362-10; Sequence=VSP_002958, VSP_009842, VSP_009843;
CC       Name=8; Synonyms=Beta B1;
CC         IsoId=P11362-4; Sequence=VSP_002958, VSP_002960;
CC       Name=9; Synonyms=Beta B2;
CC         IsoId=P11362-11; Sequence=VSP_002958, VSP_002960, VSP_009842,
CC                                   VSP_009843;
CC       Name=10; Synonyms=Gamma A1;
CC         IsoId=P11362-5; Sequence=VSP_002957;
CC       Name=11; Synonyms=Gamma A2;
CC         IsoId=P11362-12; Sequence=VSP_002957, VSP_009842, VSP_009843;
CC       Name=12; Synonyms=Gamma B1;
CC         IsoId=P11362-6; Sequence=VSP_002957, VSP_002960;
CC       Name=13; Synonyms=Gamma B2;
CC         IsoId=P11362-13; Sequence=VSP_002957, VSP_002960, VSP_009842,
CC                                   VSP_009843;
CC       Name=14; Synonyms=A, III;
CC         IsoId=P11362-7; Sequence=VSP_002959;
CC       Name=15; Synonyms=I, H3;
CC         IsoId=P11362-14; Sequence=VSP_002958, VSP_002959;
CC       Name=16; Synonyms=V;
CC         IsoId=P11362-15; Sequence=VSP_009838, VSP_009839;
CC       Name=17; Synonyms=H4;
CC         IsoId=P11362-16; Sequence=VSP_002958, VSP_009840, VSP_009841;
CC       Name=18; Synonyms=H5;
CC         IsoId=P11362-18; Sequence=VSP_002958, VSP_002959, VSP_009840,
CC                                   VSP_009841;
CC       Name=19;
CC         IsoId=P11362-19; Sequence=VSP_038470, VSP_002959, VSP_038471;
CC   -!- TISSUE SPECIFICITY: Detected in astrocytoma, neuroblastoma and
CC       adrenal cortex cell lines. Some isoforms are detected in foreskin
CC       fibroblast cell lines, however isoform 17, isoform 18 and isoform
CC       19 are not detected in these cells.
CC   -!- PTM: Binding of FGF1 and heparin promotes autophosphorylation on
CC       tyrosine residues and activation of the receptor.
CC   -!- DISEASE: Defects in FGFR1 are a cause of Pfeiffer syndrome (PS)
CC       [MIM:101600]; also known as acrocephalosyndactyly type V (ACS5).
CC       PS is characterized by craniosynostosis (premature fusion of the
CC       skull sutures) with deviation and enlargement of the thumbs and
CC       great toes, brachymesophalangy, with phalangeal ankylosis and a
CC       varying degree of soft tissue syndactyly.
CC   -!- DISEASE: Defects in FGFR1 are a cause of idiopathic
CC       hypogonadotropic hypogonadism (IHH) [MIM:146110]. IHH is defined
CC       as a deficiency of the pituitary secretion of follicle-stimulating
CC       hormone and luteinizing hormone, which results in the impairment
CC       of pubertal maturation and of reproductive function.
CC   -!- DISEASE: Defects in FGFR1 are the cause of Kallmann syndrome type
CC       2 (KAL2) [MIM:147950]; also known as hypogonadotropic hypogonadism
CC       and anosmia. Anosmia or hyposmia is related to the absence or
CC       hypoplasia of the olfactory bulbs and tracts. Hypogonadism is due
CC       to deficiency in gonadotropin-releasing hormone and probably
CC       results from a failure of embryonic migration of gonadotropin-
CC       releasing hormone-synthesizing neurons. In some cases, midline
CC       cranial anomalies (cleft lip/palate and imperfect fusion) are
CC       present and anosmia may be absent or inconspicuous.
CC   -!- DISEASE: Defects in FGFR1 are the cause of osteoglophonic
CC       dysplasia (OGD) [MIM:166250]; also known as osteoglophonic
CC       dwarfism. OGD is characterized by craniosynostosis, prominent
CC       supraorbital ridge, and depressed nasal bridge, as well as by
CC       rhizomelic dwarfism and nonossifying bone lesions. Inheritance is
CC       autosomal dominant.
CC   -!- DISEASE: Defects in FGFR1 are the cause of non-syndromic
CC       trigonocephaly [MIM:190440]; also known as metopic
CC       craniosynostosis. The term trigonocephaly describes the typical
CC       keel-shaped deformation of the forehead resulting from premature
CC       fusion of the frontal suture. Trigonocephaly may occur also as a
CC       part of a syndrome.
CC   -!- DISEASE: Note=A chromosomal aberration involving FGFR1 may be a
CC       cause of stem cell leukemia lymphoma syndrome (SCLL).
CC       Translocation t(8;13)(p11;q12) with ZMYM2. SCLL usually presents
CC       as lymphoblastic lymphoma in association with a myeloproliferative
CC       disorder, often accompanied by pronounced peripheral eosinophilia
CC       and/or prominent eosinophilic infiltrates in the affected bone
CC       marrow.
CC   -!- DISEASE: Note=A chromosomal aberration involving FGFR1 may be a
CC       cause of stem cell myeloproliferative disorder (MPD).
CC       Translocation t(6;8)(q27;p11) with FGFR1OP. Insertion
CC       ins(12;8)(p11;p11p22) with FGFR1OP2. MPD is characterized by
CC       myeloid hyperplasia, eosinophilia and T-cell or B-cell
CC       lymphoblastic lymphoma. In general it progresses to acute myeloid
CC       leukemia. The fusion proteins FGFR1OP2-FGFR1, FGFR1OP-FGFR1 or
CC       FGFR1-FGFR1OP may exhibit constitutive kinase activity and be
CC       responsible for the transforming activity.
CC   -!- DISEASE: Note=A chromosomal aberration involving FGFR1 may be a
CC       cause of stem cell myeloproliferative disorder (MPD).
CC       Translocation t(8;9)(p12;q33) with CEP110. MPD is characterized by
CC       myeloid hyperplasia, eosinophilia and T-cell or B-cell
CC       lymphoblastic lymphoma. In general it progresses to acute myeloid
CC       leukemia. The fusion protein CEP110-FGFR1 is found in the
CC       cytoplasm, exhibits constitutive kinase activity and may be
CC       responsible for the transforming activity.
CC   -!- SIMILARITY: Belongs to the protein kinase superfamily. Tyr protein
CC       kinase family. Fibroblast growth factor receptor subfamily.
CC   -!- SIMILARITY: Contains 3 Ig-like C2-type (immunoglobulin-like)
CC       domains.
CC   -!- SIMILARITY: Contains 1 protein kinase domain.
CC   -!- WEB RESOURCE: Name=Atlas of Genetics and Cytogenetics in Oncology
CC       and Haematology;
CC       URL="http://atlasgeneticsoncology.org/Genes/FGFR1113.html";
CC   -!- WEB RESOURCE: Name=GeneReviews;
CC       URL="http://www.ncbi.nlm.nih.gov/sites/GeneTests/lab/gene/FGFR1";
CC   -!- WEB RESOURCE: Name=NIEHS-SNPs;
CC       URL="http://egp.gs.washington.edu/data/fgfr1/";
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; M37722; AAA75007.1; -; mRNA.
DR   EMBL; X52833; CAA37015.1; -; mRNA.
DR   EMBL; M34185; AAA35836.1; -; mRNA.
DR   EMBL; M34186; AAA35837.1; -; mRNA.
DR   EMBL; M34187; AAA35838.1; -; mRNA.
DR   EMBL; M34188; AAA35839.1; -; mRNA.
DR   EMBL; X51803; CAA36101.1; -; mRNA.
DR   EMBL; M34641; AAA35835.1; -; mRNA.
DR   EMBL; M60485; AAA35840.1; -; mRNA.
DR   EMBL; X57118; CAA40400.1; -; mRNA.
DR   EMBL; X57119; CAA40401.1; -; mRNA.
DR   EMBL; X57120; CAA40402.1; -; mRNA.
DR   EMBL; X57121; CAA40403.1; -; mRNA.
DR   EMBL; X57122; CAA40404.1; -; mRNA.
DR   EMBL; M63887; AAA35958.1; -; mRNA.
DR   EMBL; M63888; AAA35959.1; -; mRNA.
DR   EMBL; M63889; AAA35960.1; -; mRNA.
DR   EMBL; X66945; CAA47375.1; -; mRNA.
DR   EMBL; FJ809917; ACO38646.1; -; mRNA.
DR   EMBL; AK291754; BAF84443.1; -; mRNA.
DR   EMBL; AK292470; BAF85159.1; -; mRNA.
DR   EMBL; AK222718; BAD96438.1; -; mRNA.
DR   EMBL; AY585209; AAS79322.1; -; Genomic_DNA.
DR   EMBL; BC015035; AAH15035.1; -; mRNA.
DR   EMBL; BC018128; AAH18128.1; -; mRNA.
DR   EMBL; BC091494; AAH91494.1; -; mRNA.
DR   EMBL; Y00665; CAA68679.1; -; mRNA.
DR   IPI; IPI00005142; -.
DR   IPI; IPI00012036; -.
DR   IPI; IPI00012039; -.
DR   IPI; IPI00012042; -.
DR   IPI; IPI00165947; -.
DR   IPI; IPI00216859; -.
DR   IPI; IPI00220983; -.
DR   IPI; IPI00328245; -.
DR   IPI; IPI00332838; -.
DR   IPI; IPI00410124; -.
DR   IPI; IPI00410125; -.
DR   IPI; IPI00410216; -.
DR   IPI; IPI00410217; -.
DR   IPI; IPI00410218; -.
DR   IPI; IPI00410219; -.
DR   IPI; IPI00410220; -.
DR   IPI; IPI00410223; -.
DR   IPI; IPI00455176; -.
DR   IPI; IPI00954560; -.
DR   PIR; A41266; A41266.
DR   PIR; C36464; C36464.
DR   PIR; C40862; C40862.
DR   PIR; S11692; TVHUFG.
DR   PIR; S19167; A40862.
DR   RefSeq; NP_001167534.1; -.
DR   RefSeq; NP_001167535.1; -.
DR   RefSeq; NP_001167536.1; -.
DR   RefSeq; NP_001167537.1; -.
DR   RefSeq; NP_001167538.1; -.
DR   RefSeq; NP_056934.2; -.
DR   RefSeq; NP_075593.1; -.
DR   RefSeq; NP_075594.1; -.
DR   RefSeq; NP_075598.2; -.
DR   UniGene; Hs.264887; -.
DR   PDB; 1AGW; X-ray; 2.40 A; A/B=458-765.
DR   PDB; 1CVS; X-ray; 2.80 A; C/D=141-365.
DR   PDB; 1EVT; X-ray; 2.80 A; C/D=141-365.
DR   PDB; 1FGI; X-ray; 2.50 A; A/B=458-765.
DR   PDB; 1FGK; X-ray; 2.00 A; A/B=458-765.
DR   PDB; 1FQ9; X-ray; 3.00 A; C/D=141-365.
DR   PDB; 1XR0; NMR; -; A=409-430.
DR   PDB; 2CR3; NMR; -; A=38-124.
DR   PDB; 2FGI; X-ray; 2.50 A; A/B=458-765.
DR   PDB; 3C4F; X-ray; 2.07 A; A/B=464-765.
DR   PDB; 3GQI; X-ray; 2.50 A; A=458-774.
DR   PDB; 3GQL; X-ray; 2.80 A; A/B/C=458-774.
DR   PDB; 3JS2; X-ray; 2.20 A; A/B=458-765.
DR   PDB; 3KXX; X-ray; 3.20 A; A/B/C/D=458-765.
DR   PDB; 3KY2; X-ray; 2.70 A; A/B=458-765.
DR   PDBsum; 1AGW; -.
DR   PDBsum; 1CVS; -.
DR   PDBsum; 1EVT; -.
DR   PDBsum; 1FGI; -.
DR   PDBsum; 1FGK; -.
DR   PDBsum; 1FQ9; -.
DR   PDBsum; 1XR0; -.
DR   PDBsum; 2CR3; -.
DR   PDBsum; 2FGI; -.
DR   PDBsum; 3C4F; -.
DR   PDBsum; 3GQI; -.
DR   PDBsum; 3GQL; -.
DR   PDBsum; 3JS2; -.
DR   PDBsum; 3KXX; -.
DR   PDBsum; 3KY2; -.
DR   ProteinModelPortal; P11362; -.
DR   DIP; DIP-4019N; -.
DR   IntAct; P11362; 12.
DR   MINT; MINT-1499363; -.
DR   STRING; P11362; -.
DR   PhosphoSite; P11362; -.
DR   PRIDE; P11362; -.
DR   Ensembl; ENST00000341462; ENSP00000340636; ENSG00000077782.
DR   Ensembl; ENST00000397091; ENSP00000380280; ENSG00000077782.
DR   Ensembl; ENST00000397108; ENSP00000380297; ENSG00000077782.
DR   Ensembl; ENST00000397113; ENSP00000380302; ENSG00000077782.
DR   GeneID; 2260; -.
DR   KEGG; hsa:2260; -.
DR   UCSC; uc003xlp.1; human.
DR   UCSC; uc003xlu.1; human.
DR   UCSC; uc003xlv.1; human.
DR   UCSC; uc010lwg.1; human.
DR   UCSC; uc010lwh.1; human.
DR   UCSC; uc010lwj.1; human.
DR   UCSC; uc010lwk.1; human.
DR   CTD; 2260; -.
DR   GeneCards; GC08M038287; -.
DR   HGNC; HGNC:3688; FGFR1.
DR   HPA; CAB033614; -.
DR   MIM; 101600; phenotype.
DR   MIM; 136350; gene.
DR   MIM; 146110; phenotype.
DR   MIM; 147950; phenotype.
DR   MIM; 166250; phenotype.
DR   MIM; 190440; phenotype.
DR   Orphanet; 3366; Isolated trigonocephaly.
DR   Orphanet; 478; Kallmann syndrome.
DR   Orphanet; 2326; Kallmann syndrome - heart disease.
DR   Orphanet; 168953; Myeloid neoplasm associated with FGFR1 rearrangement.
DR   Orphanet; 432; Normosmic congenital hypogonadotropic hypogonadism.
DR   Orphanet; 2645; Osteoglophonic dwarfism.
DR   Orphanet; 93258; Pfeiffer syndrome type 1.
DR   PharmGKB; PA28127; -.
DR   eggNOG; prNOG14717; -.
DR   HOVERGEN; HBG000345; -.
DR   InParanoid; P11362; -.
DR   OMA; VIVYKMK; -.
DR   BRENDA; 2.7.10.1; 247.
DR   Pathway_Interaction_DB; fgf_pathway; FGF signaling pathway.
DR   Pathway_Interaction_DB; glypican_1pathway; Glypican 1 network.
DR   Pathway_Interaction_DB; syndecan_4_pathway; Syndecan-4-mediated signaling events.
DR   Reactome; REACT_18266; Axon guidance.
DR   Reactome; REACT_498; Signaling by Insulin receptor.
DR   Reactome; REACT_9470; Signaling by FGFR.
DR   DrugBank; DB00039; Palifermin.
DR   NextBio; 9163; -.
DR   PMAP-CutDB; P11362; -.
DR   ArrayExpress; P11362; -.
DR   Bgee; P11362; -.
DR   CleanEx; HS_FGFR1; -.
DR   CleanEx; HS_FLG; -.
DR   Genevestigator; P11362; -.
DR   GermOnline; ENSG00000077782; Homo sapiens.
DR   GO; GO:0005576; C:extracellular region; NAS:UniProtKB.
DR   GO; GO:0005887; C:integral to plasma membrane; TAS:ProtInc.
DR   GO; GO:0005624; C:membrane fraction; NAS:UniProtKB.
DR   GO; GO:0005524; F:ATP binding; NAS:UniProtKB.
DR   GO; GO:0005007; F:fibroblast growth factor receptor activity; TAS:UniProtKB.
DR   GO; GO:0008201; F:heparin binding; NAS:UniProtKB.
DR   GO; GO:0016049; P:cell growth; NAS:UniProtKB.
DR   GO; GO:0000165; P:MAPKKK cascade; TAS:ProtInc.
DR   GO; GO:0006468; P:protein amino acid phosphorylation; NAS:UniProtKB.
DR   InterPro; IPR007110; Ig-like.
DR   InterPro; IPR013783; Ig-like_fold.
DR   InterPro; IPR013098; Ig_I-set.
DR   InterPro; IPR003598; Ig_sub2.
DR   InterPro; IPR011009; Kinase-like_dom.
DR   InterPro; IPR000719; Prot_kinase_cat_dom.
DR   InterPro; IPR017441; Protein_kinase_ATP_BS.
DR   InterPro; IPR001245; Ser-Thr/Tyr-Pkinase.
DR   InterPro; IPR020933; Tyr_kin_fibroblast_GF_rcpt_reg.
DR   InterPro; IPR016248; Tyr_kinase_fibroblast_GF_rcpt.
DR   InterPro; IPR020635; Tyr_Pkinase_cat_dom.
DR   InterPro; IPR020685; Tyr_prot_kinase.
DR   InterPro; IPR008266; Tyr_prot_kinase_AS.
DR   Gene3D; G3DSA:2.60.40.10; Ig-like_fold; 3.
DR   PANTHER; PTHR23256:SF276; Tyr_kinase_fibroblast_GF_rcpt; 1.
DR   PANTHER; PTHR23256; Tyr_prot_kinase; 1.
DR   Pfam; PF07679; I-set; 3.
DR   Pfam; PF07714; Pkinase_Tyr; 1.
DR   PIRSF; PIRSF000628; FGFR; 1.
DR   PRINTS; PR00109; TYRKINASE.
DR   SMART; SM00408; IGc2; 3.
DR   SMART; SM00219; TyrKc; 1.
DR   SUPFAM; SSF56112; Kinase_like; 1.
DR   PROSITE; PS50835; IG_LIKE; 3.
DR   PROSITE; PS00107; PROTEIN_KINASE_ATP; 1.
DR   PROSITE; PS50011; PROTEIN_KINASE_DOM; 1.
DR   PROSITE; PS00109; PROTEIN_KINASE_TYR; 1.
PE   1: Evidence at protein level;
KW   3D-structure; Alternative splicing; ATP-binding;
KW   Chromosomal rearrangement; Complete proteome; Craniosynostosis;
KW   Direct protein sequencing; Disease mutation; Disulfide bond; Dwarfism;
KW   Glycoprotein; Heparin-binding; Hypogonadotropic hypogonadism;
KW   Immunoglobulin domain; Kallmann syndrome; Kinase; Membrane;
KW   Nucleotide-binding; Phosphoprotein; Polymorphism; Receptor; Repeat;
KW   Signal; Transferase; Transmembrane; Transmembrane helix;
KW   Tyrosine-protein kinase.
FT   SIGNAL        1     21
FT   CHAIN        22    822       Basic fibroblast growth factor receptor
FT                                1.
FT                                /FTId=PRO_0000016780.
FT   TOPO_DOM     22    376       Extracellular (Potential).
FT   TRANSMEM    377    397       Helical; (Potential).
FT   TOPO_DOM    398    822       Cytoplasmic (Potential).
FT   DOMAIN       25    119       Ig-like C2-type 1.
FT   DOMAIN      158    246       Ig-like C2-type 2.
FT   DOMAIN      255    357       Ig-like C2-type 3.
FT   DOMAIN      478    767       Protein kinase.
FT   NP_BIND     484    492       ATP (By similarity).
FT   REGION      160    177       Heparin-binding.
FT   ACT_SITE    623    623       Proton acceptor (By similarity).
FT   BINDING     514    514       ATP (By similarity).
FT   SITE        428    429       Breakpoint for translocation to form
FT                                CEP110-FGFR1 OR FGFR1-CEP110 fusion
FT                                proteins.
FT   SITE        428    429       Breakpoint for translocation to form
FT                                FGFR1OP-FGFR1 or FGFR1-FGFR1OP fusion
FT                                proteins.
FT   SITE        428    429       Breakpoint for translocation to form
FT                                FGFR1OP2-FGFR1.
FT   SITE        766    766       Mediates interaction with PLC-gamma and
FT                                SHB.
FT   MOD_RES     653    653       Phosphotyrosine.
FT   MOD_RES     654    654       Phosphotyrosine; by autocatalysis (By
FT                                similarity).
FT   MOD_RES     766    766       Phosphotyrosine; by autocatalysis.
FT   CARBOHYD     77     77       N-linked (GlcNAc...) (Potential).
FT   CARBOHYD    117    117       N-linked (GlcNAc...) (Potential).
FT   CARBOHYD    227    227       N-linked (GlcNAc...) (Potential).
FT   CARBOHYD    240    240       N-linked (GlcNAc...) (Potential).
FT   CARBOHYD    264    264       N-linked (GlcNAc...) (Potential).
FT   CARBOHYD    296    296       N-linked (GlcNAc...).
FT   CARBOHYD    317    317       N-linked (GlcNAc...) (Potential).
FT   CARBOHYD    330    330       N-linked (GlcNAc...) (Potential).
FT   DISULFID     55    101       Potential.
FT   DISULFID    178    230       Potential.
FT   DISULFID    277    341       Potential.
FT   VAR_SEQ       1    160       Missing (in isoform 10, isoform 11,
FT                                isoform 12 and isoform 13).
FT                                /FTId=VSP_002957.
FT   VAR_SEQ      31    119       Missing (in isoform 6, isoform 7, isoform
FT                                8, isoform 9, isoform 15, isoform 17 and
FT                                isoform 18).
FT                                /FTId=VSP_002958.
FT   VAR_SEQ      32     61       QPWGAPVEVESFLVHPGDLLQLRCRLRDDV -> CPDLQEA
FT                                KSCSASFHSITPLPFGLGTRLSD (in isoform 3).
FT                                /FTId=VSP_009836.
FT   VAR_SEQ      62    822       Missing (in isoform 3).
FT                                /FTId=VSP_009837.
FT   VAR_SEQ     119    119       S -> SVPI (in isoform 19).
FT                                /FTId=VSP_038470.
FT   VAR_SEQ     120    150       DALPSSEDDDDDDDSSSEEKETDNTKPNRMP -> ACPDLQ
FT                                EAKWCSASFHSITPLPFGLGTRLSD (in isoform
FT                                16).
FT                                /FTId=VSP_009838.
FT   VAR_SEQ     148    149       Missing (in isoform 14, isoform 15,
FT                                isoform 18 and isoform 19).
FT                                /FTId=VSP_002959.
FT   VAR_SEQ     151    822       Missing (in isoform 16).
FT                                /FTId=VSP_009839.
FT   VAR_SEQ     313    391       TAGVNTTDKEMEVLHLRNVSFEDAGEYTCLAGNSIGLSHHS
FT                                AWLTVLEALEERPAVMTSPLYLEIIIYCTGAFLISCMV ->
FT                                VIMAPVFVGQSTGKETTVSGAQVPVGRLSCPRMGSFLTLQA
FT                                HTLHLSRDLATSPRTSNRGHKVEVSWEQRAAGMGGAGL
FT                                (in isoform 17 and isoform 18).
FT                                /FTId=VSP_009840.
FT   VAR_SEQ     313    360       TAGVNTTDKEMEVLHLRNVSFEDAGEYTCLAGNSIGLSHHS
FT                                AWLTVLE -> HSGINSSDAEVLTLFNVTEAQSGEYVCKVS
FT                                NYIGEANQSAWLTVTRP (in isoform 19).
FT                                /FTId=VSP_038471.
FT   VAR_SEQ     392    822       Missing (in isoform 17 and isoform 18).
FT                                /FTId=VSP_009841.
FT   VAR_SEQ     428    429       Missing (in isoform 4, isoform 5, isoform
FT                                8, isoform 9, isoform 12 and isoform 13).
FT                                /FTId=VSP_002960.
FT   VAR_SEQ     619    662       CIHRDLAARNVLVTEDNVMKIADFGLARDIHHIDYYKKTTN
FT                                GRL -> VWNLKAPLVHTPRPGSQECPGDRGQCDEDSRLWP
FT                                RTGHSPHRLL (in isoform 2, isoform 5,
FT                                isoform 7, isoform 9, isoform 11 and
FT                                isoform 13).
FT                                /FTId=VSP_009842.
FT   VAR_SEQ     663    822       Missing (in isoform 2, isoform 5, isoform
FT                                7, isoform 9, isoform 11 and isoform 13).
FT                                /FTId=VSP_009843.
FT   VARIANT      22     22       R -> S (in dbSNP:rs17175750).
FT                                /FTId=VAR_019290.
FT   VARIANT      48     48       G -> S (in IHH).
FT                                /FTId=VAR_030968.
FT   VARIANT      77     77       N -> K.
FT                                /FTId=VAR_030969.
FT   VARIANT      78     78       R -> C (in KAL2).
FT                                /FTId=VAR_030970.
FT   VARIANT      97     97       G -> D (in KAL2).
FT                                /FTId=VAR_017885.
FT   VARIANT      99     99       Y -> C (in KAL2).
FT                                /FTId=VAR_017886.
FT   VARIANT     101    101       C -> F (in KAL2).
FT                                /FTId=VAR_030971.
FT   VARIANT     102    102       V -> I (in KAL2; dbSNP:rs55642501).
FT                                /FTId=VAR_030972.
FT   VARIANT     125    125       S -> L (in a breast infiltrating ductal
FT                                carcinoma sample; somatic mutation).
FT                                /FTId=VAR_042201.
FT   VARIANT     129    129       D -> A (in KAL2).
FT                                /FTId=VAR_030973.
FT   VARIANT     167    167       A -> S (in KAL2; with cleft palate,
FT                                corpus callosum agenesis, unilateral
FT                                deafness and fusion of fourth and fifth
FT                                metacarpal bones).
FT                                /FTId=VAR_017887.
FT   VARIANT     178    178       C -> S (in KAL2; with severe ear
FT                                anomalies).
FT                                /FTId=VAR_030974.
FT   VARIANT     213    213       W -> G (in dbSNP:rs17851623).
FT                                /FTId=VAR_030975.
FT   VARIANT     224    224       D -> H (in KAL2).
FT                                /FTId=VAR_030976.
FT   VARIANT     237    237       G -> D (in KAL2).
FT                                /FTId=VAR_030977.
FT   VARIANT     237    237       G -> S (in IHH/KAL2; also found in a
FT                                family member with isolated anosmia; may
FT                                impair proper folding).
FT                                /FTId=VAR_030978.
FT   VARIANT     245    245       L -> P (in KAL2).
FT                                /FTId=VAR_030979.
FT   VARIANT     250    250       R -> W (in KAL2).
FT                                /FTId=VAR_030980.
FT   VARIANT     252    252       P -> R (in PS; seems to be a gain of
FT                                function).
FT                                /FTId=VAR_004111.
FT   VARIANT     252    252       P -> T (in a lung bronchoalveolar
FT                                carcinoma sample; somatic mutation).
FT                                /FTId=VAR_042202.
FT   VARIANT     254    254       R -> Q (in KAL2).
FT                                /FTId=VAR_030981.
FT   VARIANT     270    270       G -> D (in KAL2).
FT                                /FTId=VAR_030982.
FT   VARIANT     273    273       V -> M (in KAL2).
FT                                /FTId=VAR_030983.
FT   VARIANT     274    274       E -> G (in KAL2; also found in a family
FT                                member with isolated anosmia).
FT                                /FTId=VAR_030984.
FT   VARIANT     277    277       C -> Y (in KAL2).
FT                                /FTId=VAR_017888.
FT   VARIANT     283    283       P -> R (in KAL2).
FT                                /FTId=VAR_030985.
FT   VARIANT     300    300       I -> T (in non-syndromic trigonocephaly).
FT                                /FTId=VAR_030986.
FT   VARIANT     330    330       N -> I (in OGD).
FT                                /FTId=VAR_030987.
FT   VARIANT     332    332       S -> C (in KAL2).
FT                                /FTId=VAR_030988.
FT   VARIANT     339    339       Y -> C (in KAL2).
FT                                /FTId=VAR_030989.
FT   VARIANT     343    343       A -> V (in KAL2).
FT                                /FTId=VAR_030990.
FT   VARIANT     346    346       S -> C (in KAL2; also found in a family
FT                                member with isolated anosmia).
FT                                /FTId=VAR_030991.
FT   VARIANT     366    366       P -> L (in IHH/KAL2).
FT                                /FTId=VAR_030992.
FT   VARIANT     374    374       Y -> C (in OGD; elevated basal activity
FT                                and increased FGF2-mediated activity).
FT                                /FTId=VAR_030993.
FT   VARIANT     381    381       C -> R (in OGD).
FT                                /FTId=VAR_030994.
FT   VARIANT     520    520       A -> T (in KAL2).
FT                                /FTId=VAR_030995.
FT   VARIANT     538    538       I -> V (in KAL2).
FT                                /FTId=VAR_030996.
FT   VARIANT     607    607       V -> M (in KAL2; with bimanual
FT                                synkinesis).
FT                                /FTId=VAR_017889.
FT   VARIANT     621    621       H -> R (in KAL2).
FT                                /FTId=VAR_030997.
FT   VARIANT     622    622       R -> G (in KAL2; with severe ear
FT                                anomalies).
FT                                /FTId=VAR_030998.
FT   VARIANT     622    622       R -> Q (in KAL2).
FT                                /FTId=VAR_030999.
FT   VARIANT     664    664       V -> L (in a lung large cell carcinoma
FT                                sample; somatic mutation).
FT                                /FTId=VAR_042203.
FT   VARIANT     666    666       W -> R (in KAL2; with cleft palate).
FT                                /FTId=VAR_017890.
FT   VARIANT     685    685       S -> F (in KAL2).
FT                                /FTId=VAR_031000.
FT   VARIANT     687    687       G -> R (in KAL2).
FT                                /FTId=VAR_031001.
FT   VARIANT     693    693       I -> F (in KAL2).
FT                                /FTId=VAR_031002.
FT   VARIANT     703    703       G -> R (in KAL2).
FT                                /FTId=VAR_031003.
FT   VARIANT     703    703       G -> S (in KAL2).
FT                                /FTId=VAR_031004.
FT   VARIANT     719    719       M -> R (in KAL2).
FT                                /FTId=VAR_017891.
FT   VARIANT     722    722       P -> H (in IHH; associated with K-724;
FT                                also found in a family member with
FT                                isolated anosmia; reduced tyrosine kinase
FT                                activity).
FT                                /FTId=VAR_031005.
FT   VARIANT     722    722       P -> S (in KAL2).
FT                                /FTId=VAR_031006.
FT   VARIANT     724    724       N -> K (in IHH; associated with H-722;
FT                                also found in a family member with
FT                                isolated anosmia; reduced tyrosine kinase
FT                                activity).
FT                                /FTId=VAR_031007.
FT   VARIANT     745    745       P -> S (in KAL2).
FT                                /FTId=VAR_031008.
FT   VARIANT     769    769       L -> V (in dbSNP:rs2956723).
FT                                /FTId=VAR_031009.
FT   VARIANT     772    772       P -> S (in KAL2; with cleft palate,
FT                                unilateral absence of nasal cartilage,
FT                                iris coloboma; dbSNP:rs56234888).
FT                                /FTId=VAR_017892.
FT   VARIANT     795    795       V -> I (in KAL2; also found in a family
FT                                member with isolated anosmia).
FT                                /FTId=VAR_031010.
FT   VARIANT     818    818       G -> R (in dbSNP:rs17182456).
FT                                /FTId=VAR_019291.
FT   VARIANT     822    822       R -> C (in dbSNP:rs17182463).
FT                                /FTId=VAR_019292.
FT   MUTAGEN     766    766       Y->F: Fails to interact with PLC-gamma
FT                                and SHB.
FT   CONFLICT     24     24       S -> C (in Ref. 8; AAA35958/AAA35959).
FT   CONFLICT    192    192       K -> E (in Ref. 3; AAA35837).
FT   CONFLICT    194    194       G -> S (in Ref. 5; AAA35835).
FT   CONFLICT    196    196       E -> G (in Ref. 15).
FT   CONFLICT    223    223       S -> F (in Ref. 12; BAD96438).
FT   CONFLICT    308    308       V -> A (in Ref. 8; AAA35958/AAA35959).
FT   CONFLICT    364    364       E -> Q (in Ref. 17; CAA68679).
FT   CONFLICT    469    469       P -> L (in Ref. 1; AAA75007).
FT   CONFLICT    482    482       K -> R (in Ref. 12; BAD96438).
FT   CONFLICT    576    576       R -> W (in Ref. 12; BAD96438).
FT   CONFLICT    817    817       G -> R (in Ref. 4; CAA36101).
FT   STRAND      151    156
FT   HELIX       158    161
FT   STRAND      165    169
FT   STRAND      174    177
FT   STRAND      180    184
FT   STRAND      187    192
FT   HELIX       199    201
FT   STRAND      207    209
FT   TURN        210    213
FT   STRAND      214    219
FT   HELIX       222    224
FT   STRAND      226    234
FT   STRAND      237    248
FT   STRAND      265    267
FT   STRAND      273    276
FT   STRAND      286    293
FT   STRAND      295    297
FT   STRAND      306    313
FT   HELIX       320    323
FT   STRAND      325    328
FT   HELIX       333    335
FT   STRAND      337    344
FT   STRAND      349    358
FT   TURN        469    471
FT   HELIX       475    477
FT   STRAND      478    483
FT   STRAND      492    498
FT   STRAND      508    514
FT   HELIX       522    538
FT   STRAND      547    551
FT   STRAND      553    556
FT   STRAND      558    561
FT   HELIX       569    574
FT   HELIX       597    616
FT   HELIX       626    628
FT   STRAND      629    631
FT   STRAND      637    639
FT   HELIX       648    650
FT   HELIX       663    666
FT   HELIX       669    674
FT   HELIX       679    693
FT   TURN        694    696
FT   HELIX       706    714
FT   HELIX       727    736
FT   HELIX       741    743
FT   HELIX       747    760
SQ   SEQUENCE   822 AA;  91868 MW;  93A01B5D78C3E72C CRC64;
     MWSWKCLLFW AVLVTATLCT ARPSPTLPEQ AQPWGAPVEV ESFLVHPGDL LQLRCRLRDD
     VQSINWLRDG VQLAESNRTR ITGEEVEVQD SVPADSGLYA CVTSSPSGSD TTYFSVNVSD
     ALPSSEDDDD DDDSSSEEKE TDNTKPNRMP VAPYWTSPEK MEKKLHAVPA AKTVKFKCPS
     SGTPNPTLRW LKNGKEFKPD HRIGGYKVRY ATWSIIMDSV VPSDKGNYTC IVENEYGSIN
     HTYQLDVVER SPHRPILQAG LPANKTVALG SNVEFMCKVY SDPQPHIQWL KHIEVNGSKI
     GPDNLPYVQI LKTAGVNTTD KEMEVLHLRN VSFEDAGEYT CLAGNSIGLS HHSAWLTVLE
     ALEERPAVMT SPLYLEIIIY CTGAFLISCM VGSVIVYKMK SGTKKSDFHS QMAVHKLAKS
     IPLRRQVTVS ADSSASMNSG VLLVRPSRLS SSGTPMLAGV SEYELPEDPR WELPRDRLVL
     GKPLGEGCFG QVVLAEAIGL DKDKPNRVTK VAVKMLKSDA TEKDLSDLIS EMEMMKMIGK
     HKNIINLLGA CTQDGPLYVI VEYASKGNLR EYLQARRPPG LEYCYNPSHN PEEQLSSKDL
     VSCAYQVARG MEYLASKKCI HRDLAARNVL VTEDNVMKIA DFGLARDIHH IDYYKKTTNG
     RLPVKWMAPE ALFDRIYTHQ SDVWSFGVLL WEIFTLGGSP YPGVPVEELF KLLKEGHRMD
     KPSNCTNELY MMMRDCWHAV PSQRPTFKQL VEDLDRIVAL TSNQEYLDLS MPLDQYSPSF
     PDTRSSTCSS GEDSVFSHEP LPEEPCLPRH PAQLANGGLK RR
//
